CDDO-TFEA (Synonyms: CDDO-Trifluoethyl Amide,RTA 404,TP-500) |
| رقم الكتالوجGC16625 |
Nrf2 activator
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 932730-52-4
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
CDDO-trifluoroethyl-amide (CDDO-TFEA), a trifluoroethylamide derivative of CDDO, is an Nrf2/ARE pathway activator [1][2][3].
The NF-E2-related factor-2 (Nrf2)/antioxidant response element (ARE) signaling pathway is an important pathway involved in antioxidant and anti-inflammatory responses. Modulation of the Nrf2/ARE pathway is an attractive therapeutic target for neurodegenerative diseases such as amyotrophic lateral sclerosis (ALS) and Huntington's disease (HD) [2][3].
CDDO-TFEA is an Nrf2/ARE pathway activator. In NSC-34 G93A SOD1 cells, CDDO-TFEA upregulated Nrf2 expression and caused translocation of Nrf2 into the nucleus. CDDO-TFEA also increased the expression of Nrf2/ARE-regulated proteins (NQO-1, HO-1 and Glutathione reductase).
In mice with experimental autoimmune encephalomyelitis (EAE), CDDO-TFEA reduced immune and inflammatory cell populations. CDDO-TFEA also significantly reduced Th1 and Th17 cytokines (IL6, IL17, IFNγ, TNFα and GMCSF) [1]. In ALS mice model, CDDO-TFEA upregulated the expression and resulted in translocation of Nrf2 to the nucleus of neurons in the spinal cord. In G93A SOD1 mice, CDDO-TFEA increased the life-span by 17.6 days [2].
References:
[1]. Pareek TK, Belkadi A, Kesavapany S, et al. Triterpenoid modulation of IL-17 and Nrf-2 expression ameliorates neuroinflammation and promotes remyelination in autoimmune encephalomyelitis. Sci Rep. 2011;1:201.
[2]. Neymotin A, Calingasan NY, Wille E, et al. Neuroprotective effect of Nrf2/ARE activators, CDDO ethylamide and CDDO trifluoroethylamide, in a mouse model of amyotrophic lateral sclerosis. Free Radic Biol Med. 2011 Jul 1;51(1):88-96.
[3]. Stack C, Ho D, Wille E, et al. Triterpenoids CDDO-ethyl amide and CDDO-trifluoroethyl amide improve the behavioral phenotype and brain pathology in a transgenic mouse model of Huntington's disease. Free Radic Biol Med. 2010 Jul 15;49(2):147-58.
| Cas No. | 932730-52-4 | SDF | |
| المرادفات | CDDO-Trifluoethyl Amide,RTA 404,TP-500 | ||
| Chemical Name | 2-cyano-3,12-dioxo-N-(2,2,2-trifluoroethyl)-oleana-1,9(11)-dien-28-amide | ||
| Canonical SMILES | CC1(CC[C@@]2(CC[C@@](C)([C@@]3(CC[C@]4(C(C)(C(C(C#N)=C[C@@]4(C3=CC5=O)C)=O)C)[H])C)[C@]5([C@@]2(C1)[H])[H])C(NCC(F)(F)F)=O)C | ||
| Formula | C33H43F3N2O3 | M.Wt | 572.7 |
| الذوبان | ≤5mg/ml in ethanol;5mg/ml in DMSO;5mg/ml in dimethyl formamide | Storage | Store at -20°C |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 1.7461 mL | 8.7306 mL | 17.4611 mL |
| 5 mM | 0.3492 mL | 1.7461 mL | 3.4922 mL |
| 10 mM | 0.1746 mL | 0.8731 mL | 1.7461 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 29 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *